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Introduction
Sleep disorders are common in patients with epilepsy. In addition to excessive daytime sleepiness (EDS), many primary sleep disorders such as obstructive sleep apnea (OSA), and sleepmaintenance insomnia are 2 to 3 times more prevalent in people with epilepsy than the general populations [1] . Also, sleep in these patients may be adversely affected by nocturnal epileptiform discharges/seizures and antiepileptic drugs (AEDs). Co-morbid sleep problems in turn, lead to a poorer quality of life in adults [2] [3] [4] and have negative effects on daytime behaviour and academic performance in children and adolescents [5, 6] . Moreover, sleep and epilepsy have a complex bidirectional interrelationship. Sleep is also known to influence epilepsy, in relation to clinical as well as electrophysiological expression. Both NREM and REM sleep stages have contrasting effects on generalized ictal and interictal epileptiform discharges. These discharges are likely to propagate during NREM sleep, while REM sleep is resistant to their propagation [7] . Focal IEDs may increase in frequency and tend to become bilateral and generalized during slow wave sleep [8] [9] [10] . While idiopathic generalized epilepsies frequently have EDs in the lighter stages of NREM sleep [11] [12] [13] . The ability of NREM sleep to activate IEDs is attributed to the occurrence of neuronal synchronization between brainstem, thalamus and cortex. Occurrence of these epileptic EEG potentials result in repeated arousals and sleep fragmentation. This leads to episodic day time sleepiness and acts as a trigger for seizures and epileptiform discharges, thereby forming a vicious cycle. Juvenile myoclonic epilepsy (JME) is a primary generalized epilepsy syndrome that has an intimate relationship with sleep cycle. It has its onset in mid-adolescence, and is characterized by myoclonic, absence, and generalized tonicclonic seizures, usually occurring shortly after arousal. There are a few studies that have evaluated the sleep quality and its architecture in patients of JME [12] [13] [14] [15] [16] [17] . Most of these are limited by small number of patients and with confounding effect of antiepileptic drugs. The present study sought to assess the sleep quality and its architecture, assess the occurrence of epileptiform discharges and their distribution across various stages of sleep in a larger cohort of juvenile myoclonic epilepsy (JME) patients.
Materials and methods
This was a prospective cross-sectional observational study, in 99 consecutive patients of juvenile myoclonic epilepsy(age group 5-50 years, any gender) diagnosed according to International League against epilepsy (ILAE) criteria [18, 19] Sleep quality was evaluated by Pittsburgh Sleep Quality Index (PSQI) [20] and day time sleepiness by Epworth Sleepiness Scale (ESS) [21] . Sleep architecture was assessed by overnight polysomnography (PSG) [22] . The PSG was performed in a dedicated sleep lab with a maintained comfortable temperature, and hypnogram for each case was obtained. The PSG recording was carried out using an eight-channel EEG, ECG, chin electromyography (EMG), right anterior tibialis EMG, electro-oculogram, nasal thermistor, snore monitor, chest and abdominal movements monitor, pulse rate recorder, and oximetry.
The scoring of sleep and related events was done manually as per the American Academy of Sleep Medicine 2012 version 2 guidelines [22] . Sleep parameters like sleep duration, sleep onset latency, sleep staging, wakefulness after sleep onset, sleep efficiency, REM latency, duration of REM, arousal index, apnoeahypopnea index, cardiac events, periodic limb movements of sleep (PLMS) were recorded.
The epileptiform discharges (EDs), namely spike/polyspikeslow wave complexes and occasional spikes, were identified and quantified throughout each PSG. The number of each ED event was noted across all stages of sleep. The EDI (Epileptiform Discharge Index) per stage of sleep was calculated using the number of EDs in each sleep stage (in minutes) as well as in WASO.
The patients were divided into two groups: a) Drug naïve JME patients. b) Drug treatment group [on any antiepileptic drug].The Table 1 Clinical profile of JME patients (Drug naïve and drug treatment).
Parameters
All patients n = 99 
Statistical analysis
Statistical analysis was done with SPSS software version 20. Data was expressed as mean AE standard deviation, median (range) and percentages. Student-t-test and Chi square/Fisher exact test were applied to compare the association between quantitative and categorical data respectively. ANOVA (analysis of variance) was applied if the quantitative variable was compared in more than two groups. Post-hoc analysis was applied after ANOVA test when p value was significant. Non parametric tests like Mann Whitney and Kruskal Wallis were used for data that was not normally distributed. The level of significance was set at 0.05. The bar diagram was made using Excel sheet.
Results

Demographic and clinical profile
The study had 99 patients of JME Table 1 . Various anti epileptic drugs being taken by the patients are mentioned in Table 2. 24.2% of the patients with JME reported family history of seizures. One patient of JME had experienced febrile seizure at the age of 1 year. Focal onset of seizures was seen in a single patient, with a similar history in the family. Sleep deprivation [68.7%] was seen as the most common precipitator for seizures, followed by stress [33 
Epileptiform discharges
Routine, 16-channel, awake EEG revealed normal background in all the patients. The epileptiform discharges (EDs) were noted during the awake part of the routine EEG with significant abnormalities seen in drug naïve patients, 75% vs. 34.9%, treatment group. All the controls had normal awake record.
Sixty (Table 3) 
Sleep quality and daytime sleepiness
Whole cohort versus controls
The quality of sleep among JME patients was poor in comparison to controls [median PSQI score of 4(0-11) vs. 3(1-7), respectively; p = 0.02)]. PSQI score > 5 (suggestive of poor quality of sleep) was seen in 27(27.3%) patients and 5 healthy controls (16.7%). ESS was found to be higher among patients as compared to controls [median score (Range), 6(0-24) vs. 4(1-13), respectively; p = 0.06]. ESS score > 10 (suggesting excessive day time sleepiness) was seen in 13(13.1%) patients as compared to 2, in control group[score, 11 and 13].
Subgroup analysis
On individual comparison of drug naïve and on treatment patients with controls, a similar trend of abnormalities in sleep quality indices was seen, as with whole cohort (Table 3 ). There was no significant difference between patients who were drug naïve and those on treatment ( Table 3 ). The same was true even among patients with ESS score > 10 [mean score and SD,14.7 AE 6.2 vs 12.5 AE 1.1, drug naïve and on treatment groups, respectively, p = 0.7] 3.5. Sleep architecture (Table 4) 3.
Whole cohort versus controls
The total sleep time was of shorter duration and sleep efficiency was poorer in the JME group vs the control group [patients: 74.9 AE 17.0 (%), controls: 88.3 AE 8. 
Subgroup analysis
The abnormalities in sleep architecture followed a similar trend as the whole cohort, when the drug naïve and on treatment groups were compared to controls on an individual basis ( Table 4 (Table 4) .
Duration of treatment and dose of valproate
Median (range) treatment duration was 36(3-216) months (Table 2 ). The% N2 sleep showed an increment with the duration of treatment (p = 0.04), Table 5 . Further, valproate in higher dosage ( > 400 mg) increased the% N2 sleep (p = 0.009), and decreased%N3 (p = 0.09) and% REM sleep (p = 0.05), Table 6 .
Respiratory events and cardiac events
Respiratory events were seen in 8 patients and none of the controls, however, median apnoea hypopnea index (AHI) was normal. No significant cardiac rate and rhythm disturbances were noted in any of the patients or controls.
Discussion
This study presents the largest available data on evaluation of sleep parameters in JME patients, including the drug naïve ones. The clinical and demographic profile was similar to previous reports on JME [23] [24] [25] [26] [27] [28] . There was a female preponderance (male: female ratio of 1:2) in the cohort. Myoclonus was present in all patients, GTCS in 96% and absence seizures in 9%. GTCS had predilection to occur in early morning. Pure nocturnal seizures were seen in 8.1% patients. Similar circadian predilection with higher seizure occurrence on awakening has been observed by various authors.
Sleep disturbances
JME patients had a poor quality of sleep (higher median PSQI scores, p = 0.02), in comparison to healthy controls. The daytime sleepiness was not much different from the controls. The total sleep time (p = 0.07) and sleep efficiency (p < 0.001) were reduced in the patients. There was difficulty in initiation (higher median sleep latency in patients, p = 0.02) and maintenance of sleep. They had increased wakefulness in sleep (WASO, p < 0.001) and increased% N1 sleep (p = 0.01). REM sleep latency was prolonged (p = 0.1) and significantly reduced% REM sleep (p = 0.002). Some patients did not achieve REM at all, during the sleep cycles. Both the drug naïve and treatment groups followed a similar trend of abnormalities when compared individually to controls.
There are a few studies available in literature, all from one centre, that have evaluated sleep quality and polysomnography in JME patients (Table 8 ) [12, 17] . Krishnan P et al found reduced mean % N2 and mean total NREM sleep in JME patients [16] . Contrary to their observations, we found significantly reduced percentage of REM and increased% N1 sleep, ( Table 4, Table 7 ). The sleep scores were by and large similar to our cohort.
On comparing the drug naive and treatment groups, we did not observe a significant difference in most of the sleep parameters, except a reduced percentage of slow wave sleep (N3) in the drug treatment group (p = 0.002). Also, valproate in higher dosage (> 400 mg) reduced%N3 (p = 0.09) and increased% N2 (p = 0.009) Data is in Mean AE SD and Median (Range);p < 0.05 is taken as significant. sleep. The%N2 also increased with the duration of treatment (p = 0.04). The above results imply that the quality and architecture of sleep is disturbed predominantly by the disease itself, with some additional contribution of antiepileptic drug. Furthermore, valproate in higher dosages and longer treatment duration disrupt slow wave sleep and increase N2 of NREM sleep. Previous studies on the effect of drugs on sleep in JME patients have reported similar results [14, 16] . Krishnan P et al, in their study on 25 patients of JME on valproate, found that, those on valproate therapy for >1 year, had a longer duration of stage N2 and prolonged N3 latency [16] . Nayak et al, reported significant alterations in REM arousal indices and several cyclic alternating pattern parameters in Table 7 Epileptiform discharge Index among JME patients. Data is in Mean AE SD, p < 0.05 is taken as significant, NREM sleep stage; N1,N2, N3; WASO: wake after sleep onset.
Table 8
Comparative studies on sleep quality and architect in JME. drug naive JME patients and postulated that valproate may beneficially modulate arousal instability in JME patients [8] . We found a lower median N2 arousal index in the treatment group (p = 0.049) and some reduction in the overall median arousal index with a longer duration of treatment (> 60 months) but the change was not statistically significant (p = 0.1). Valproate has been reported to alter sleep architecture but with conflicting results [29] [30] [31] .
Effect of sleep on epileptiform discharges
Sleep has a modulating effect on the distribution of EDs in different forms of epilepsy. Epileptiform discharges occur more commonly in NREM sleep, which acts as the precipitating factor for EDs [32] [33] [34] [35] than the REM sleep which is an inhibitor [34, [36] [37] [38] . The present study showed higher EDs in N1 and N2 sleep in JME patients irrespective of their treatment status, similar to the observations in previous studies [17, 39] . Furthermore, the drug naïve JME patients had higher epileptiform discharge indices in N1 (p < 0.001) and N2 (p = 0.007) sleep, compared to patients on treatment. Ramachandraiah et al reported increased EDs in REM sleep in drug naïve JME patients [17] . We had only two patients with EDs in REM, and both were drug naïve. The observation of relatively lower EDI in treatment group with valproate, compared to other drugs implies that treatment, in particular, with valproate has a beneficial effect on epileptiform discharges in JME.
The findings of this study have important pathophysiological implications on the association of epilepsy and sleep in JME. Most of the sleep disturbances seen in epilepsy patients are either attributed to drugs or to the destabilizing effect of epileptiform activity on the mechanisms of sleep. We found a similar trend of abnormalities in both drug naive and treatment groups, thus reflecting an association of sleep abnormalities with the disease per se. Previous studies in JME have reported that, frequent epileptiform discharges during NREM sleep can lead to macro arousals and stage shifts [17] . Epileptiform discharges in JME patients have also been reported to be associated with higher rates of cyclic alternating patterns leading to sleep instability [12, 13] .
Alternatively, the sleep abnormalities in JME may represent an 'essential' comorbid problem, sharing common pathophysiological pathways with the epileptogenic process, and may be independent of seizure control [40] . JME has a polygenetic inheritance, and two of the genes responsible for the pathogenesis of JME are GABRA1 gene on chromosome 5q. and GABRD gene on chromosome 1p [41] . These encode subunits of the GABA Alpha and delta receptor, respectively. The effect of defective GABA receptors is the loss of inhibitory signals with resultant increase in the cortical excitability. On the other hand, GABA is a crucial mediator of sleep architect, as GABA-ergic REM on and off neurons stabilize the flip flop switch, permitting NREM-REM cycling. Experimental studies have shown that optogenetic activation of ventral medullary GABAergic neurons (rostral projections) can modulate the initiation as well as duration of REM sleep [42] . We found absent to decreased REM and increased%N1 sleep, in a significant number of patients, along with instability of light NREM sleep in the drug naive group. It is possible, that in JME patients, light NREM sleep remains the dominant one in the later part of night in contrast to the usual pattern of REM dominance in the later sleep cycles, predisposing them to early morning seizures.
Future studies should thus address, alterations in pathways common to the pathophysiology of both sleep and epilepsy, like the GABAergic pathway, to better understand the disease and its comorbidities.
To conclude, JME is associated with an alteration in sleep architecture, with poor quality of sleep, irrespective of whether the patient is drug naive or on treatment. REM sleep is significantly decreased in JME patients with an increase in N1 sleep duration. Epileptiform discharges are frequent in lighter NREM sleep, in JME patients. Furthermore, EDI is higher in drug naïve patients. Although AEDs disrupt the NREM sleep, their use is associated with arousal stability in lighter stages of NREM sleep and lower epileptiform discharge indices, especially with valproate.
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